Ovarian Cancer

Researchers have developed a new screening approach that produces very few false positives in postmenopausal women with an average risk of ovarian cancer.

Continued use of the targeted drug Avastin (bevacizumab), after initial treatment with the drug and chemotherapy, helped slow progression of advanced ovarian cancer, according to a phase 3 study.

Updates from the annual meeting of the American Society of Clinical Oncology.

Treating an ovarian cancer relapse as soon as it can be detected seems like a good idea. But not so fast, a major study has concluded.

Ovarian cancer survivors ponder implications of CA-125 study.

News from the 2009 annual meeting of the American Society of Clinical Oncology.

Results from an international study challenge current practice of screening for ovarian cancer relapse.

Controlling lymphedema with the old and the new.

Ovarian cancer, also known as “the silent killer,” may soon be detected earlier, giving women improved survival rates, with the recognition of specific early warning signs which including abdominal pain, abdominal bloating, urinary urgency or frequency, pelvic and lower back pressure, loss of appetite or feeling full quickly and abnormal vaginal bleeding.

Paying attention to early symptoms of ovarian cancer may give a voice to the "silent killer," but some advise caution.

Ovarian cancer survivor advocates led the way for scientific studies of early symptoms of ovarian cancer and are ultimately responsible for the recognition and consensus statement on the warning signs by the medical community.

Ovarian Cancer Alliance launches social networking site.

This article discusses genetic test kits and the types of cancer they test for.

The individual & family decisions behind testing for genetic cancer risk.

Learning about one's genetic status may open a Pandora's box of personal and familial issues.

This article discusses premature menopause as a result of cancer treatments.